Symphony Allegro Overview
- Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
1
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
Symphony Allegro General Information
Description
Developer of Alexza Pharmaceuticals' AZ-002 and AZ-004 products. The company was formed through a collaboration between Symphony Capital Partners and Alexza Pharmaceuticals to develop Alexza's AZ-002 Staccato Alprazolam and AZ-004 Staccato Loxapine programs. It supports AZ-002 through Phase IIb clinical trials for the treatment of panic attack in patients with panic disorder and AZ-004 through Phase IIb clinical trials for the treatment of acute agitation in patients with schizophrenia.
Contact Information
Website
www.symphonyallegro.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- 7361 Calhoun Place
- Suite 325
- Rockville, MD 20855
- United States
+1 (301) 000-0000
Symphony Allegro Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Symphony Allegro Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Frank Hurley Ph.D | Chief Executive Officer | ||
| Daniel Salins | Chief Financial Officer | ||
| Robert Smith Jr. | Treasurer |
Symphony Allegro Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Symphony Allegro Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|